Pathophysiology and pharmacological targets of VEGF in diabetic macular edema

被引:51
作者
Fogli, Stefano [1 ]
Mogavero, Selene [2 ]
Egan, Colin Gerard [2 ]
Del Re, Marzia [1 ]
Danesi, Romano [1 ]
机构
[1] Univ Pisa, Dept Clin & Expt Med, I-56100 Pisa, Italy
[2] Primula Multimedia SrL, Pisa, Italy
关键词
Diabetic macular edema; Diabetic retinopathy; VEGF; Angiogenesis; Inflammation; ENDOTHELIAL GROWTH-FACTOR; BLOOD-RETINAL BARRIER; AQUEOUS CONCENTRATIONS; INTRAVITREAL INJECTION; VITREOUS FLUID; INFLAMMATORY CYTOKINES; SOLUBLE CD14; IN-VIVO; INTERLEUKIN-6; RANIBIZUMAB;
D O I
10.1016/j.phrs.2015.11.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Diabetic macular edema (DME) is a serious condition that can cause blindness in diabetic patients suffering from diabetic retinopathy (DR). Although vascular endothelial growth factor (VEGF) is known to play a role in the development of DME, the pathological processes leading to the onset of this disease are highly complex and the exact sequence in which they occur is still not completely understood. Angiogenesis and inflammation have been shown to be involved in the pathogenesis of this disease. However, it still remains to be clarified whether angiogenesis following VEGF over-expression is a cause or a consequence of inflammation. Here, we provide an overview of the current data available in the literature focusing on VEGF, angiogenesis, inflammation, DR and DME. Our analysis suggests that angiogenesis and inflammation act interdependently during the development of DME. VEGF is a critical player in the molecular crosstalk occurring between these two processes, reinforcing the use of anti-VEGF agents for the treatment of DME. (C) 2015 Published by Elsevier Ltd.
引用
收藏
页码:149 / 157
页数:9
相关论文
共 82 条
[1]   VEGF modulation of retinal pigment epithelium resistance [J].
Ablonczy, Zsolt ;
Crosson, Craig E. .
EXPERIMENTAL EYE RESEARCH, 2007, 85 (06) :762-771
[2]   Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor [J].
Aiello, LP ;
Bursell, SE ;
Clermont, A ;
Duh, E ;
Ishii, H ;
Takagi, C ;
Mori, F ;
Ciulla, TA ;
Ways, K ;
Jirousek, M ;
Smith, LEH ;
King, GL .
DIABETES, 1997, 46 (09) :1473-1480
[3]   Clinical trials on corticosteroids for diabetic macular edema [J].
Al Dhibi, Hassan A. ;
Arevalo, J. Fernando .
WORLD JOURNAL OF DIABETES, 2013, 4 (06) :295-302
[4]   Vitreous levels of soluble vascular endothelial growth factor receptor (VEGFR)-1 in eyes with vitreoretinal diseases [J].
Asato, Ryo ;
Kita, Takeshi ;
Kawahara, Shuhei ;
Arita, Ryoichi ;
Mochizuki, Yasutaka ;
Aiello, Lloyd Paul ;
Ishibashi, Tatsuro .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2011, 95 (12) :1745-1748
[5]   Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD [J].
Avery, Robert L. ;
Castellarin, Alessandro A. ;
Steinle, Nathan C. ;
Dhoot, Dilsher S. ;
Pieramici, Dante Joseph ;
See, Robert ;
Couvillion, Stephen ;
Nasir, Ma'an A. ;
Rabena, Melvin D. ;
Le, Kha ;
Maia, Mauricio ;
Visich, Jennifer E. .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2014, 98 (12) :1636-1641
[6]  
Bandello F., 2015, CURR PHARM DES
[7]   Population pharmacokinetics of pegaptanib sodium (Macugen (R)) in patients with diabetic macular edema [J].
Basile, Anthony S. ;
Hutmacher, Matthew M. ;
Kowalski, Kenneth G. ;
Gandelman, Kuan Y. ;
Nickens, Dana J. .
CLINICAL OPHTHALMOLOGY, 2015, 9 :323-335
[8]   Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy [J].
Behl, Tapan ;
Kotwani, Anita .
PHARMACOLOGICAL RESEARCH, 2015, 99 :137-148
[9]   Diabetic Macular Edema: Pathogenesis and Treatment [J].
Bhagat, Neelakshi ;
Grigorian, Ruben A. ;
Tutela, Arthur ;
Zarbin, Marco A. .
SURVEY OF OPHTHALMOLOGY, 2009, 54 (01) :1-32
[10]   Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood [J].
Bremnes, RM ;
Camps, C ;
Sirera, R .
LUNG CANCER, 2006, 51 (02) :143-158